Detection of Autoantibodies by 2D-immunoblotting.

<p>(<b>A</b>) The 2-DE protein pattern after CBB staining. Immunoblot analysis with mixed sera from patients with psoriasis vulgaris (<b>B</b>) and psoriatic arthritis (<b>C</b>) as primary antibodies, respectively. Several proteins were positively detected as autoantigens in each disease.</p

Autoantigens identified using sera from psoriasis vulgaris patients.

<p>Autoantigens identified using sera from psoriasis vulgaris patients.</p

Clinical characteristics of psoriasis patients.

<p>Clinical characteristics of psoriasis patients.</p

Expression of moesin (A, B, C), K17 (D, E, F), STIP1 (G, H, I), and ANXA1 (J, K, L) in psoriasis vulgaris (A, D, G, J), psoriatic arthritis (B, E, H, K), and control (C, F, I, L).

<p>Different expression levels of moesin, K17, STIP1, and ANXA1 were observed in epidermis of psoriasis vulgaris and psoriatic arthritis, but weak expressions were detected in the epidermis of normal skin. Bar = 200 µm.</p

Serum moesin (A and B), K17 (C and D), and STIP1 (E, F and G) levels in patients with psoriasis vulgaris, psoriatic arthritis, and healthy controls.

<p>(A) Serum moesin levels were significantly higher in psoriasis vulgaris and psoriatic arthritis patients compared to healthy controls (*: <i>P</i><0.05 and §: <i>P</i><0.001, respectively). (B) Receiver-operating characteristic curve (ROC) analysis of moesin as a serum marker for psoriasis vulgaris or psoriatic arthritis. The corresponding area under the curve (AUC) was 0.747 for psoriasis vulgaris. With a 76.9% specificity, the sensitivity of moesin for psoriasis vulgaris was 71.0% at a cut-off value corresponding to 146.6. (C) Serum K17 levels were significantly higher in psoriatic arthritis than in healthy controls and psoriasis vulgaris (*: <i>P</i><0.05, $: <i>P</i><0.01). (D) ROC analysis of K17 as a serum marker for psoriatic arthritis. AUC was 0.72 for psoriatic arthritis. With a 80.6% specificity, the sensitivity of K17 for psoriatic arthritis was 66.7% at a cut-off value corresponding to 439.5. (E) Serum STIP1 levels were significantly higher in psoriasis vulgaris and psoriatic arthritis compared to healthy controls (<i>P</i><0.005 each). Serum STIP1 levels were also significantly higher in psoriatic arthritis compared to healthy controls or psoriasis vulgaris (*: <i>P</i><0.05, **: <i>P</i><0.005, #: <i>P</i><0.005). (F) ROC analysis of STIP1 as a serum marker for psoriatic vulgaris. AUC was 0.79 for psoriatic vulgaris. With a 69.2% pecificity, the sensitivity of Stip-1 for psoriatic arthritis was 80.7% at a cut-off value corresponding to 105.8. (G) ROC of STIP1 as a serum marker for psoriatic arthritis. AUC was 0.70 for psoriatic arthritis. With a 42.9% specificity, the sensitivity of STIP1 for psoriatic arthritis was 66.7% at a cut-off value corresponding to 195.4.</p

Autoantigens identified using sera from psoriatic arthritis patients<b>.</b>

<p>Autoantigens identified using sera from psoriatic arthritis patients<b>.</b></p

Immunohistochemical screening of the Ku-Lu-6 antibody with AMeX-fixed LCN1-cis (A) and LCN1 (B) cells.

<p>Membranous staining was observed in LCN1-cis cells, but not in LCN1 cells. (original magnification: A, B ×400).</p

Relationships between MYH9 Expression and Clinicopathological parameters.

<p>* See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0121460#pone.0121460.t001" target="_blank">Table 1</a> for explanation of abbreviations and note on asterisk.</p><p>Relationships between MYH9 Expression and Clinicopathological parameters.</p

Representative immunohistochemical staining for MYH9 in NSCLC.

<p>A: MYH9 was strongly expressed in the membrane of tumor cells in adenocarcinoma. B: MYH9 was strongly expressed in the membrane and cytoplasm of tumor cells in squamous cell carcinoma. (original magnification: A, B ×400).</p

Antibody absorption test for MYH9.

<p>KU-LU-6 antibody supernatant was pre-absorbed with none (A), 0.12 ug (B), 0.24 ug (C), and 0.48 ug (D) of synthetic MYH9 proteins. Each absorbed antibody was immunostained with formalin-fixed LC2/ad-cis cells. The stainability of KU-Lu-6 antibody was gradually reduced depending on the concentration of MYH9 protein.</p